Aerami Therapeutics raises capital to advance PHT treatment


After making leadership adjustments following the death of its CEO, a Durham pharmaceutical company is now looking to raise up to $20 million.

Previous D.C.-based Incapsulate acquired by Accenture
Next Exclusive: Xcel confirms move of Denver regional headquarters